The 2',3'-cAMp-adenosine pathway

American Journal of Physiology - Renal Physiology

Volumn 301, Issue 6, 2011, Pages

  Jackson, Edwin K ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

2' AMP; 3' AMP; Kidney

Indexed keywords

ADENOSINE; ADENOSINE 2',3' PHOSPHATE; CYCLIC AMP; MESSENGER RNA; RIBONUCLEASE;

APOPTOSIS; CELL DAMAGE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY PERFUSION; MESANGIUM CELL; MITOCHONDRIAL PERMEABILITY; NECROSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; RENAL PROTECTION; REVIEW; SECOND MESSENGER; TANDEM MASS SPECTROMETRY; VASCULAR SMOOTH MUSCLE;

EID: 82755162678     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00450.2011     Document Type: Review

References (96)

1. Akahane M, Ono H, Ohgushi H, Takakura Y. Viability of ischemia/ reperfused bone determined at the gene expression level. J Reconstr Microsurg 17: 203-209, 2001.
2. Akahane M, Ono H, Ohgushi H, Tamai S. Viability of ischemia/ reperfused muscles in rat: a new evaluation method by RNA degradation. J Orthop Res 19: 559-564, 2001.
3. Alberts B, Bray D, Lewis J, Raff M, Roberts K, Watson JD. The CELL Nucleus. In: Molecular Biology of The Cell (2nd ed.). New York: Garlan, 1989, p. 481-550.
4. Albig AR, Decker CJ. The target of rapamycin signaling pathway regulates mRNA turnover in the yeast Saccharomyces cerevisiae. Mol Biol Cell 12: 3428-3438, 2001.
5. Almeida A, Paul Thiery J, Magdelenat H, Radvanyi F. Gene expression analysis by real-time reverse transcription polymerase chain reaction: influence of tissue handling. Anal Biochem 328: 101-108, 2004.
6. +-dependent permeability transition regulation in rat brain mitochondria by 2',3'-cyclic nucleotides and 2',3'-cyclic nucleotide 3'-phosphodiesterase. Am J Physiol Cell Physiol 296: C1428-C1439, 2009.
7. Banholzer R, Nair AP, Hirsch HH, Ming XF, Moroni C. Rapamycin destabilizes interleukin-3 mRNA in autocrine tumor cells by a mechanism requiring an intact 3' untranslated region. Mol Cell Biol 17: 3254-3260, 1997.
8. Borst P, de Wolf C, van de Wetering K. Multidrug resistance-associated proteins 3, 4, and 5. Pflügers Arch 453: 661-673, 2007.
9. Bushfield M, Shoshani I, Johnson RA. Tissue levels, source, and regulation of 3'-AMP: an intracellular inhibitor of adenylyl cyclases. Mol Pharmacol 38: 848-853, 1990.
10. Catts VS, Catts SV, Fernandez HR, Taylor JM, Coulson EJ, Lutze- Mann LH. A microarray study of post-mortem mRNA degradation in mouse brain tissue. Brain Res 138: 164-177, 2005.
11. Cheng D, Ren J, Jackson EK. Multidrug resistance protein 4 mediates cAMP efflux from rat preglomerular vascular smooth muscle cells. Clin Exp Pharmacol Physiol 37: 205-207, 2010.
12. Chevyreva I, Faull RLM, Green CR, Nicholson LFB. Assessing RNA quality in postmortem human brain tissue. Exp Mol Pathol 84: 71-77, 2008.
13. Chiavegatti T, Costa VL Jr, Araujo MS, Godinho RO. Skeletal muscle expresses the extracellular cyclic AMP-adenosine pathway. Br J Pharmacol 153: 1331-1340, 2008.
14. Day YJ, Huang L, Ye H, Linden J, Okusa MD. Renal ischemiareperfusion injury and adenosine 2A receptor-mediated tissue protection: role of macrophages. Am J Physiol Renal Physiol 288: F722-F731, 2005.
15. Deeley RG, Westlake C, Cole SPC. Transmembrane transport of endoand xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol Rev 86: 849-899, 2006.
16. Del Prete MJ, Robles MS, Guao A, Martinez AC, Izquierdo M, Garcia-Sanz JA. Degradation of cellular mRNA is a general early apoptosis-induced event. FASEB J 16: 2003-2005, 2002.
17. Denatale G, Causa P, Coscia L. Su alcune attività farmacologiche del 2' AMP, del 3' AMP del 2'-3' AMP in confront con il 5' AMP. Arch Ital Sci Farmacol 13: 169-172, 1963.
18. Deussen A, Lloyd HG, Schrader J. Contribution of S-adenosylhomocysteine to cardiac adenosine formation. J Mol Cell Cardiol 21: 773, 1989.
19. Deussen A, Pexa A, Loncar R, Stehr SN. Effects of homocysteine on vascular and tissue adenosine: a stake in homocysteine pathogenicity? Clin Chem Lab Med 43: 1007-1010, 2005.
20. Do T, Sun Q, Beuve A, Kuzhikandathil EV. Extracellular cAMP inhibits D1 dopamine receptor expression in CAD catecholaminergic cells via A2a adenosine receptors. J Neurochem 101: 619-631, 2007.
21. Dubey RK, Gillespie DG, Jackson EK. Cyclic AMP-adenosine pathway induces nitric oxide synthesis in aortic smooth muscle cells. Hypertension 31: 296-302, 1998.
22. Dubey RK, Gillespie DG, Mi Z, Jackson EK. Cardiac fibroblasts express the cAMP-adenosine pathway. Hypertension 36: 337-342, 2000.
23. Dubey RK, Gillespie DG, Mi Z, Jackson EK. Endogenous cyclic AMP-adenosine pathway regulates cardiac fibroblast growth. Hypertension 37: 1095-1100, 2001.
24. Dubey RK, Gillespie DG, Mi Z, Jackson EK. Extracellular 3',5'-cyclic AMP-adenosine pathway inhibits glomerular mesangial cell growth. J Pharmacol Exp Ther 333: 808-815, 2010.
25. Dubey RK, Gillespie DG, Shue H, Jackson EK. A2B receptors mediate antimitogenesis in vascular smooth muscle cells. Hypertension 35: 267-272, 2000.
26. Dubey RK, Jackson EK, Rupprecht HD, Sterzel RB. Factors controlling growth and matrix production in vascular smooth muscle and glomerular mesangial cells. Curr Opin Nephrol Hypertens 6: 88-105, 1997.
27. Dubey RK, Mi Z, Gillespie DG, Jackson EK. Cyclic AMP-adenosine pathway inhibits vascular smooth muscle cell growth. Hypertension 28: 765-771, 1996.
28. Eckle T, Grenz A, Laucher S, Eltzschig HK. A2B adenosine receptor signaling attenuates acute lung injury by enhancing alveolar fluid clearance in mice. J Clin Invest 118: 3301-3315, 2008.
29. Eltzschig HK, Abdulla P, Hoffman E, Hamilton KE, Daniels D, Schonfeld C, Loffler M, Reyes G, Duszenko M, Karhausen J, Robinson A, Westerman KA, Coe IR, Colgan SP. HIF-1-dependent repression of equilibrative nucleoside transporter (ENT) in hypoxia. J Exp Med 202: 1493-1505, 2005.
30. Fiszman ML, Stefano FJ. Amphetamine-clonidine interaction on neurotransmission in the vas deferens of the rat. Naunyn Schmiedebergs Arch Pharmacol 328: 148-153, 1984.
31. Fleming WA, McNeill TA. Cellular responsiveness to stimulation in vitro: increased responsiveness to colony stimulating factor of bone marrow colony-forming cells treated with surface-active agents and cyclic 3'5' AMP. J Cell Physiol 88: 323-329, 1976.
32. Fuhr JE, Stidham JD. Inhibitory effect of cyclic adenosine 2',3'- monophosphate on leucine incorporation by L5178Y cells. J Cell Physiol 103: 71-75, 1980.
33. Fujimori H, Pan-Hou H. Formation of adenosine 3'-monophosphate in rat liver mitochondria. Biol Pharm Bull 21: 624-627, 1998.
34. Fujimori H, Sato R, Yasuda M, Pan-Hou H. A specific and rapid method for determination of adenosine 3'-monophosphate (3'-AMP) content and 3'-AMP forming enzyme activity in rat liver mitochondria, using reversed-phase HPLC with fluorescence detection. Biol Pharm Bull 21: 1348-1351, 1998.
35. Garrison JC, Haynes RC Jr. The hormonal control of gluconeogenesis by regulation of mitochondrial pyruvate carboxylation in isolated rat liver cells. J Biol Chem 250: 2769-2777, 1975.
36. Giron MC, Bin A, Brun P, Etteri S, Bolego C, Florio C, Gaion RM. Cyclic AMP in rat ileum: evidence for the presence of an extracellular cyclic AMP-adenosine pathway. Gastroenterology 134: 1116-1126, 2008.
37. Grenz A, Osswald H, Eckle T, Yang D, Zhang H, Tran ZV, Klingel K, Ravid K, Eltzschig HK. The reno-vascular A2B adenosine receptor protects the kidney from ischemia. PLoS 5: e137, 2008.
38. Hartzell HC. Adenosine receptors in frog sinus venosus: slow inhibitory potentials produced by adenine compounds and acetylcholine. J Physiol 293: 23-49, 1979.
39. Hashemolhosseini S, Nagamine Y, Morley SJ, Desrivieres S, Mercep L, Ferrari S. Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability. J Biol Chem 273: 14424-14429, 1998.
40. Hong KW, Shin HK, Kim HH, Choi JM, Rhim BY, Lee WS. Metabolism of cAMP to adenosine: role in vasodilation of rat pial artery in response to hypotension. Am J Physiol Heart Circ Physiol 276: H376-H382, 1999.
41. Ichikawa A, Esumi K, Takagi M, Yatsunami K, Negishi M, Yokoyama K, Tomita K. Effect of adenosine and adenosine 5'-monophosphate on cell division of cultured mastocytoma P-815 cells. J Pharmacobiodyn 3: 123-135, 1980.
42. Jackson EK. Adenosine: a physiological brake on renin release. Annu Rev Pharmacol Toxicol 31: 1-35, 1991.
43. Jackson EK, Dubey RK. Role of the extracellular cAMP-adenosine pathway in renal physiology. Am J Physiol Renal Physiol 281: F597-F612, 2001.
44. Jackson EK, Gillespie DG, Dubey RK. 2'-AMP and 3'-AMP inhibit proliferation of preglomerular vascular smooth muscle cells and glomerular mesangial cells via A2B receptors. J Pharmacol Exp Ther 337: 444-450, 2011.
45. Jackson EK, Mi Z. Preglomerular microcirculation expresses the cAMPadenosine pathway. J Pharmacol Exp Ther 295: 23-28, 2000.
46. Jackson EK, Mi Z. Regulation of renal ectophosphodiesterase by protein kinase C and sodium diet. J Pharmacol Exp Ther 325: 210-216, 2008.
47. Jackson EK, Mi Z, Gillespie DG, Dubey RK. Metabolism of cAMP to adenosine in the renal vasculature. J Pharmacol Exp Ther 283: 177-182, 1997.
48. Jackson EK, Mi Z, Zacharia LC, Tofovic SP, Dubey RK. The pancreatohepatorenal cAMP-adenosine mechanism. J Pharmacol Exp Ther 321: 799-809, 2007.
49. Jackson EK, Mi Z, Zhu C, Dubey RK. Adenosine biosynthesis in the collecting duct. J Pharmacol Exp Ther 307: 888-896, 2003.
50. Jackson EK, Raghvendra DK. The extracellular cyclic AMP-adenosine pathway in renal physiology. Annu Rev Physiol 66: 571-599, 2004.
51. Jackson EK, Ren J, Cheng D, Mi Z. Extracellular cAMP-adenosine pathways in the mouse kidney. Am J Physiol Renal Physiol 301: F565-F573, 2011.
52. Jackson EK, Ren J, Gillespie DG. 2',3'-cAMP, 3'-AMP and 2'-AMP inhibit human aortic and coronary vascular smooth muscle cell proliferation via A2B receptors. Am J Physiol Heart Circ Physiol 301: H391-H401, 2011.
53. Jackson EK, Ren J, Gillespie DG, Dubey RK. Extracellular 2',3'-cyclic adenosine 5'-monophosphate is a potent inhibitor of preglomerular vascular smooth muscle cell and mesangial cell growth. Hypertension 56: 151-158, 2010.
54. Jackson EK, Ren J, Mi Z. Extracellular 2',3'-cAMP is a source of adenosine. J Biol Chem 284: 33097-33106, 2009.
55. Jackson EK, Ren J, Zacharia LC, Mi Z. Characterization of renal ecto-phosphodiesterase. J Pharmacol Exp Ther 321: 810-815, 2007.
56. Jackson EK, Zacharia LC, Zhang M, Gillespie DG, Zhu C, Dubey RK. cAMP-adenosine pathway in the proximal tubule. J Pharmacol Exp Ther 317: 1219-1229, 2006.
57. Kim M, Chen SWC, Park SW, Kim M, D'Agati VD, Yang J, Lee HT. Kidney-specific reconstitution of the A1 adenosine receptor in A1 adenosine receptor knockout mice reduces renal ischemia-reperfusion injury. Kidney Int 75: 809-823, 2009.
58. Kloor D, Osswald H. S-Adenosylhomocysteine hydrolase as a target for intracellular adenosine action. Trends Pharmacol Sci 25: 294-297, 2004.
59. Kroemer G, Galluzzi L, Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol Rev 87: 99-163, 2007.
60. Kruh GD, Zeng H, Rea PA, Liu G, Chen ZS, Lee K, Belinsky MG. MRP subfamily transporters and resistance to anticancer agents. J Bioenerg Biomembr 33: 493-501, 2001.
61. Kuzhikandathil EV, Clark L, Li Y. The extracellular cAMP-adenosine pathway regulates expression of renal D1 dopamine receptors in diabetic rats. J Biol Chem 286: 32454-32463, 2011.
62. Lee HT, Emala CW. Adenosine attenuates oxidant injury in human proximal tubular cells via A1 and A2a adenosine receptors. Am J Physiol Renal Physiol 282: F844-F852, 2002.
63. Lee HT, Emala CW. Protective effects of renal ischemic preconditioning and adenosine pretreatment: role of A1 and A3 receptors. Am J Physiol Renal Physiol 278: F380-F387, 2000.
64. Lee HT, Kim M, Jan M, Penn RB, Emala CW. Renal tubule necrosis and apoptosis modulation by A1 adenosine receptor expression. Kidney Int 71: 1249-1261, 2007.
65. Lee KS, Schubert P, Emmert H, Kreutzberg GW. Effect of adenosine versus adenine nucleotides on evoked potentials in a rat hippocampal slice preparation. Neurosci Lett 23: 309-314, 1981.
66. Lloyd HG, Deussen A, Wuppermann H, Schrader J. The transmethylation pathway as a source for adenosine in the isolated guinea-pig heart. Biochem J 252: 489-494, 1988.
67. Lu B, Rajakumar SV, Robson SC, Lee EKF, Crikis S, d'Apice AJF, Cowan PJ, Dwyer KM. The impact of purinergic signaling on renal ischemia-reperfusion injury. Transplantation 86: 1707-1712, 2008.
68. Mi Z, Herzer WA, Zhang Y, Jackson EK. 3-Isobutyl-1-methylxanthine decreases renal cortical interstitial levels of adenosine and inosine. Life Sci 54: 277-282, 1994.
69. Mi Z, Jackson EK. Evidence for an endogenous cAMP-adenosine pathway in the rat kidney. J Pharmacol Exp Ther 287: 926-930, 1998.
70. Mi Z, Jackson EK. Metabolism of exogenous cyclic AMP to adenosine in the rat kidney. J Pharmacol Exp Ther 273: 728-733, 1995.
71. Miyamoto A, Takeshita M, Pan-Hou H, Fujimori H. Hepatic changes in adenine nucleotide levels and adenosine 3'-monophosphate forming enzyme in streptozotocin-induced diabetic mice. J Toxicol Sci 33: 209-217, 2008
72. Morote-Garcia JC, Rosenberger P, Nivillac NMI, Coe IR, Eltzschig HK. Hypoxia-inducible factor-dependent repression of equilibrative nucleoside transporter 2 attenuates mucosal inflammation during intestinal hypoxia. Gastroenterology 136: 607-618, 2009.
73. Müller G, Wied S, Over S, Frick W. Inhibition of lipolysis by palmitate, H2O2 and the sulfonylurea drug, glimepiride, in rat adipocytes depends on cAMP degradation by lipid droplets. Biochemistry 47: 1259-1273, 2008.
74. Nakane T, Chiba S. Pharmacological analysis of vasodilation induced by extracellular adenosine 3',5'-cyclic monophosphate in the isolated and perfused canine coronary artery. J Pharmacol Exp Ther 264: 1253-1261, 1993.
75. Okusa MD. A2A adenosine receptor: a novel therapeutic target in renal disease. Am J Physiol Renal Physiol 282: F10-F18, 2002.
76. Okusa MD, Linden J, Huang L, Rieger JM, Macdonald TL, Huynh LP. A2A adenosine receptor-mediated inhibition of renal injury and neutrophil adhesion. Am J Physiol Renal Physiol 279: F809-F818, 2000.
77. Okusa MD, Linden J, Huang L, Rosin DL, Smith DF, Sullivan G. Enhanced protection from renal ischemia-reperfusion injury with A2Aadenosine receptor activation and PDE 4 inhibition. Kidney Int 59: 2114-2125, 2001.
78. Okusa MD, Linden J, Macdonald T, Huang L. Selective A2A adenosine receptor activation reduces ischemia-reperfusion injury in rat kidney. Am J Physiol Renal Physiol 277: F404-F412, 1999.
79. Oshima N, Furuuchi T, Fujii R. Cyclic nucleotide action is mediated through adenosine receptors in damselfish motile iridophores. Comp Biochem Physiol C 85: 89-93, 1986.
80. Pabst M, Grass J, Fischl R, Léonard R, Jin C, Hinterkörner G, BorthN, Altmann F. Nucleotide and nucleotide sugar analysis by liquid chromatography- electrospray ionization-mass spectrometry on surface-conditioned porous graphitic carbon. Anal Chem 82: 9782-9788, 2010.
81. Rao F, Qi Y, Murugan E, Pasunooti S, Ji Q. 2',3'-cAMP hydrolysis by metal-dependent phosphodiesterases containing DHH, EAL, and HD domains is non-specific: Implications for PDE screening. Biochem Biophys Res Commun 398: 500-505, 2010.
82. Ren J, Mi Z, Stewart NA, Jackson EK. Identification and quantification of 2',3'-cAMP release by the kidney. J Pharmacol Exp Ther 328: 855-865, 2009.
83. Rosenberger P, Schwab JM, Mirakaj V, Masekowsky E, Mager A, Morote-Garcia JC, Unertl K, Eltzschig HK. Hypoxia-inducible factordependent induction of netrin-1 dampens inflammation caused by hypoxia. Nature Immunol 10: 195-202, 2009.
84. Sarkar D, Fisher PB. Human polynucleotide phosphorylase (hPNPase old-35): an RNA degradation enzyme with pleiotrophic biological effects. Cell Cycle 5: 1080-1084, 2006.
85. Schmidt S. Candidate autoantigens in multiple sclerosis. Mult Scler 5: 147-160, 1999.
86. Sorrentino S. Human extracellular ribonucleases: multiplicity, molecular diversity and catalytic properties of the major RNase types. Cell Mol Life Sci 54: 785-794, 1998.
87. Sorrentino S, Libonati M. Structure-function relationships in human ribonucleases: main distinctive features of the major RNase types. FEBS Lett 404: 1-5, 1997.
88. Sprinkle TJ. 2',3'-cyclic nucleotide 3'-phosphodiesterase, an oligodendrocyte- Schwann cell and myelin-associated enzyme of the nervous system. Crit Rev Neurobiol 4: 235-301, 1989.
89. Thompson JE, Venegas FD, Raines RT. Energetics of catalysis by ribonucleases: fate of the 2',3'-cyclic phosphodiester intermediate. Biochemistry 33: 7408-7414, 1994.
90. Thompson RJ. 2',3'-cyclic nucleotide-3'-phosphohydrolase and signal transduction in central nervous system myelin. Biochem Soc Trans 20: 621-626, 1992.
91. van Aubel R, Smeets PHE, Peters JGP, Bindels RJM, Russel FGM. The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J Am Soc Nephrol 13: 595, 2002.
92. Verrier JD, Exo JL, Jackson TC, Ren J, Gillespie DG, Dubey RK, Kochanek PM, Jackson EK. Expression of the 2',3'-cAMP-adenosine pathway in astrocytes and microglia. J Neurochem. [Epub before print].
93. Vogel US, Thompson RJ. Molecular structure, localization, and possible functions of the myelin-associated enzyme 2',3'-cyclic nucleotide 3'- phosphodiesterase. J Neurochem 50: 1667-1677, 1988.
94. Wahn HL, Lightbody LE, Tchen TT, Taylor JD. Induction of neural differentiation in cultures of amphibian undetermined presumptive epidermis by cyclic AMP derivatives. Science 188: 366-369, 1975.
95. Willemot J, Paton DM. Metabolism and presynaptic inhibitory activity of 2',3' and 5'-adenine nucleotides in rat vas deferens. Naunyn Schmiedebergs Arch Pharmacol 317: 110-114, 1981.
96. Wilusz CJ, Wormington M, Peltz SW. The cap-to-tail guide to mRNA turnover. Nat Rev Mol Cell Biol 2: 237-246, 2001.